Immunotherapy
Can Targeted Radiotherapy and a Combination of Antibodies Pack More Punch in Boosting the Immune System to Destroy Cancer Cells?
Can Targeted Radiotherapy and a Combination of Antibodies Pack More Punch in Boosting the Immune System to Destroy Cancer Cells? Project Title: A Phase I Study of 131-1 mIBG, Nivolumab, and Dinutuximab-beta in Relapsed / Refractory Neuroblastoma (MiNivAn) Researcher: Juliet Gray, MD Institution: University Hospital Southampton, University of Wisconsin-Madison, Greifswald, Germany Study Type: Phase I clinical…
Read MoreCan the Polio Virus Stop Deadly Brain Tumors?
The virus is delivered via a catheter directly into the tumor by a method known as convection-enhanced delivery. This clinical project fills a significant unmet need for children with high-risk brain tumors. PVSRIPO for Recurrent Malignant Glioma in Children Project Title: Phase I study of an oncolytic polio/rhinovirus recombinant (PVS-RIPO) against recurrent pediatric high-grade glioma…
Read MoreAre Five Targets Better Than One? Using CTLs To Seek and Destroy
This immunotherapy treatment uses cytotoxic T lymphocytes (CTLs) for the first-time for children with neuroblastoma. CTLs are the killer T-cells of the immune system whose role is to seek out and destroy abnormal cells. Project Title: Phase I Clinical Trial of Tumor Associated Antigen-Specific CTLs for Neuroblastoma Researcher: Chris DeRenzo, MD Institution: Baylor College of…
Read MoreCan T-Cell Immunotherapy Work in Osteosarcoma and Neuroblastoma?
This trial studies the side effects and best dose of activated T cells armed with GD2 bispecific antibody and how well they work in treating patients with neurblastoma, osteosarcoma, and other GD2+ solid tumors. Project Title: Activated T-Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcomas Researcher: Maxim Yankelevich,…
Read MoreCan Nivolumab Treat Childhood Brain Tumors?
Recent results from clinical trials in adults with various tumor types have shown exciting results. Nivolumab has not yet been studied in any children with brain tumors. Project Title: Anti-PD1 Nivolumab in Children With Brain Tumors Researcher: Ira Dunkel, MD Institution: Memorial Sloan-Kettering Cancer Center; Johns Hopkins University Hospital Study Type: Phase II Clinical Trial…
Read MoreCan a Child’s T-Cells be Engineered to Better Recognize and Kill Neuroblastoma Cells Safely?
Solving Kids’ Cancer supported the preclinical work that led to this current clinical trial using a CAR T-cell therapy approach with the goal of bringing these early successes in blood cancers to children with neuroblastoma and other solid tumors. This new method enhances proliferation and persistence and a safety switch. Project Title: Activated T-Cells Transduced…
Read MoreWill a New Drug That Stops Cell Repair Reduce Tumors in Children When Given With Chemotherapy?
Researchers at CHOP identified an enzyme that plays a key role in controlling the cell cycle a called checkpoint kinase or CHK1. The Wee1 inhibitor MK-1775 works with irinotecan to stop cell division and cause cell death. This combination drug treatment is being tested in children with neuroblastoma and medulloblastoma. Project Title: Ph I/II MK-1775…
Read MoreWill an Antibody Recognizing a New Target in Neuroblastoma Kill Tumor Cells?
In the lab, an antibody targeting ALK expression kills neuroblastoma cells. Researchers believe that an anti-ALK antibody that targets the surface antigen will alert the immune system to attack the cancer, reducing the risk of a future recurrence. This research is to develop, test, and produce clinical grade anti-ALK antibody. Project Title: Preclinical Development of…
Read MoreCan a Vaccine Made From a Child’s Immune Cells Work Against Deadly Brain Tumors?
This new treatment targets glioma-associated antigens, which are overexpressed in ependymomas, making them ideal candidates for the immunotherapy researchers previously developed. This cutting-edge research represents the first immunotherapy trial ever for kids with ependymomas. Project Title: Pilot Study Peptide-based vaccination for recurrent ependymomas Researcher: Ian F. Pollack, MD Institution: Children’s Hospital of Pittsburgh Study Type:…
Read MoreCan Engineered T-Cells Be Improved to Better Recognize and Attack Neuroblastoma Cells?
T-cell therapy has seen much success in leukemia patients. Researchers now are trying to find out if T-cell therapy using the GD2 tumor antigen, which is on the surface of the neuroblastoma cancer cells, can bring about remission in solid tumors. Project Title: Adoptive Cell Therapy for Adolescent/pediatric Solid Tumors: Part II Researcher: Stephen Grupp,…
Read More